Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Feigelson, Heather Spencer, Zeng, Chan, Pawloski, Pamala A., Onitilo, Adedayo A., Richards, C. Sue, Johnson, Monique A., Kauffman, Tia L., Webster, Jennifer, Nyirenda, Carsie, Alexander, Gwen L., Hwang, Clara, Cross, Deanna, McCarty, Catherine A., Davis, Robert L., Schwarzkopf, Denise, Williams, Andrew E., Honda, Stacey, Daida, Yihe, Kushi, Lawrence H., Delate, Thomas, Goddard, Katrina A. B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4006772/
https://ncbi.nlm.nih.gov/pubmed/24788807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0094977
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky